Bioavailability and Safety Study Comparing Two Dose Levels of AMZ001 and One Dose Level of Diclofenac Sodium 1% Gel in Healthy Participants

NCT05968482 | Completed Phase 1 Results FDA Drug

• 1 other identifier: AMZ001-008
• Study Type: interventional
• Target: 74
• Locations: 1 country
• Sites: 1

Brief Summary

The goal of this clinical trial is to compare drug exposure from two different products (AMZ001 and Diclofenac Sodium 1% Gel) in healthy participants on Day 7 after repeated topical administrations for 7 days. Participants will receive, in a crossover design, three different treatments

• AMZ001 Low dose
• AMZ001 High dose
• Diclofenac Sodium 1% Gel Safety and tolerability of AMZ001 will be also investigated.

Conditions

Healthy

Outcome Measures

Primary Outcomes (2)

• Compare Exposure to Diclofenac

  Area under the curve (AUC) from time zero to 24 hours

  Day 7

• Pharmacokinetic Parameter - Cmax

  Maximum plasma drug concentration (Cmax)

  Day 1

Secondary Outcomes (7)

• Pharmacokinetic Parameter - Cmin

  Day 7

• Pharmacokinetic Parameter - Tmax

  Day 7

• Pharmacokinetic Parameter - Ke

  Day 7

• Pharmacokinetic Parameter - Cavg

  Day 7

• Pharmacokinetic Parameter - Tmax

  Day 1

Study Arms (3)

AMZ001 Low dose

EXPERIMENTAL

AMZ001 applied once daily for 7 consecutive days

Drug: Diclofenac Sodium Gel

AMZ001 High dose

EXPERIMENTAL

AMZ001 applied once daily for 7 consecutive days

Drug: Diclofenac Sodium Gel

Diclofenac Sodium 1% Gel

ACTIVE COMPARATOR

Reference product applied four-times daily for 7 consecutive days

Drug: Diclofenac Sodium Gel

Interventions

Diclofenac Sodium Gel DRUG

Topical application on both knees

AMZ001 High dose; AMZ001 Low dose; Diclofenac Sodium 1% Gel

Eligibility Criteria

• Age: 18 Years - 65 Years
• Sex: all
• Healthy Volunteers: Yes
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Healthy male or female participants 18-65 years of age (e.g., in general good physical health, as judged by the Investigator and no clinically relevant abnormalities identified by a detailed medical history, full physical examination, including blood pressure and pulse rate measurement, 12-lead ECG (electrocardiogram) or clinical laboratory tests)
• Has a body mass index (BMI) between 18.0 and 35.0 kg/m\^2 (kilogram per square meter) at Screening.
• In the case of females of child-bearing potential (\[FCBP) unless surgically sterilized \[hysterectomy, bilateral oophorectomy, bilateral tubal ligation\] or are postmenopausal for at least 12 months), are using two acceptable forms of birth control (hormonal contraceptives i.e., oral/implant/injectable/transdermal; intrauterine device (IUD) and/or barrier methods \[female condom, male condom, diaphragm, cervical cap, spermicide\]; note: 2 barrier methods are two acceptable forms of birth control)). Abstinence or partner's vasectomies are acceptable if the female participant agrees to implement two acceptable forms of birth control if her lifestyle/partner changes.
• Females of child-bearing potential have a negative serum pregnancy test (SPT) at Screening and negative urine pregnancy test (UPT) on Day -1 of each period and at end of treatment (EOT) visit
• Are free of any systemic or dermatologic disorder and chronic or acute infections, which, in the opinion of the Principal Investigator (PI), will interfere with the study results or increase the risk of adverse events (AEs)
• Read, understand, and provide signed informed consent before any assessment is performed.

You may not qualify if:

• Participant has any visible skin disease, skin lesions, wounds, or a significant amount of hair at the application site (knee)
• Use of an investigational medicinal product (IMP) within 30 days or 5 half-lives (if known), whichever is longer, of enrollment or during the study.
• Treated with systemic or local diclofenac within 30 days of enrollment or during the study (except for study IMP)
• Known hypersensitivity to diclofenac, aspirin, Xarelto, coumadin, or other non-steroidal anti-inflammatory drugs (NSAIDs), including Cyclooxygenase-2 (COX-2) inhibitors.
• Any history of drug hypersensitivity, asthma, urticaria, or other significant allergic diathesis. Participants with uncomplicated seasonal allergic rhinitis can be accepted only if the expected allergy season is clearly outside enrollment / treatment periods.
• Females who are pregnant and/or lactating
• Of child-bearing potential but not willing to use adequate contraception for the duration of the study
• Participant is a current smoker and unable to abstain from smoking during the treatment periods.
• Use of any topical medication, cosmetics, cream, ointments, lotions on the treatment site 1 week prior to enrollment through EOT visit
• Use of any medication (including over-the-counter medication, dietary supplements, and herbal remedies) within 2 weeks before first scheduled study drug administration or within less than 5 times the elimination half-life of the respective drug (whichever is longer) or is anticipated to require concomitant medication during the 2-week period or at any time throughout the study. Consumption of any drug metabolizing enzyme (e.g., cytochrome P450 3A4 (CYP3A4) or other cytochrome P450 enzymes) inducing or inhibiting beverages or food (e.g., broccoli, Brussel sprouts, grapefruit, grapefruit juice, star fruit) within 3 days prior to and during each treatment period
• Participant has a known or suspected malignancy, excluding basal cell cancer unless it is associated with the treatment area.
• Participant has a positive blood screen for human immunodeficiency virus (HIV), hepatitis B surface antigen (HBsAg), hepatitis C antibody (Anti-HCV)
• Participant has any acute or chronic condition or is using medications, which, in the investigator's opinion, would make it unsafe for the participant to participate in this study, including clinically significant abnormal laboratory values, vital signs, physical examination findings prior to randomization or during study participation.
• History or current evidence of renal disease or impaired renal function at screening as indicated by abnormal levels of serum creatinine (greater than (\>) 1.43 mg/dL (milligram per deciliter)) or blood urea nitrogen (greater than or equal to (≥) 35 mg/dL) or the presence of clinical significant abnormal urinary constituents (e.g., albuminuria)
• History or current evidence of ongoing hepatic disease or impaired hepatic function at screening. A participant will be excluded if more than one of the following lab value deviations are found: 1) aspartate aminotransferase (AST) (≥ 1.5 upper limit of normal (ULN)), alanine aminotransferase (ALT) (≥ 1.5 ULN), 2) Gamma-Glutamyl Transferase (GGT) (≥ 1.5 ULN), alkaline phosphatase (ALP) (≥ 1.5 ULN), 3) total bilirubin (\> 2.00 mg/dL) or creatine kinase (≥ 3 ULN). A single deviation from the above values is acceptable and will not exclude the participant, unless specifically advised by the Investigator.

Sponsors & Collaborators

• Amzell: lead

Study Sites (1)

TKL Research

Fair Lawn, New Jersey, 07410, United States

Location

Results Point of Contact

• Title: Chief Executive Officer
• Organization: Amzell BV

amzell-disclosure@amzell.com

+31235560460

Publication Agreements

• PI is Sponsor Employee: No
• Restriction Type: OTHER
• Restrictive Agreement: Yes

Study Design

• Study Type: interventional
• Phase: phase 1
• Allocation: RANDOMIZED
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: CROSSOVER
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: July 7, 2023
• First Posted: August 1, 2023
• Study Start: July 11, 2023
• Primary Completion: December 27, 2023
• Study Completion: December 2, 2024
• Last Updated: April 9, 2025
• Results First Posted: April 9, 2025

Record last verified: 2025-03

Data Sharing

• IPD Sharing: Will not share

Locations

US (1)